睿知中国医院研究地图
候选清单

沈阳中国医科大学

中国医科大学附属第一医院

First Hospital of China Medical University

在本站收录的 53 种疾病中,这家医院列在其中 29 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

中国医科大学附属第一医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma7 篇牵头论文
  3. 肝细胞癌Hepatocellular carcinoma61 篇牵头论文牵头 2 项开放试验
  4. 胃癌Stomach cancer109 篇牵头论文牵头 1 项开放试验
  5. 脊索瘤Chordoma0 篇牵头论文
  6. 骨肉瘤Osteosarcoma5 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour6 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma2 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma4 篇牵头论文
  11. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia0 篇牵头论文
  12. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis2 篇牵头论文
  13. 血友病 AHaemophilia A1 篇牵头论文
  14. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
  15. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder6 篇牵头论文
  16. IgG4相关性疾病IgG4-related disease6 篇牵头论文
  17. 重症肌无力Myasthenia gravis9 篇牵头论文
  18. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
  19. 大动脉炎Takayasu arteritis0 篇牵头论文
  20. 特发性肺纤维化Idiopathic pulmonary fibrosis3 篇牵头论文
  21. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis3 篇牵头论文
  22. 法布雷病Fabry disease0 篇牵头论文
  23. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  24. IgA 肾病IgA nephropathy4 篇牵头论文
  25. 成骨不全症Osteogenesis imperfecta1 篇牵头论文
  26. 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
  27. 原发性硬化性胆管炎Primary sclerosing cholangitis2 篇牵头论文
  28. 遗传性大疱性表皮松解症Inherited epidermolysis bullosa1 篇牵头论文
  29. 遗传性血管性水肿Hereditary angioedema0 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、再生障碍性贫血、β 地中海贫血、非典型溶血性尿毒症综合征、范可尼贫血、烟雾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 0020242025: 222025

沈阳有 2 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题放疗技术副作用与生活质量免疫治疗
论文中的科室耳鼻喉/头颈外科放疗科
牵头的论文5
  1. PTEN as a prognostic factor for radiotherapy plus immunotherapy response in nasopharyngeal carcinoma.2025Journal of nanobiotechnology免费全文
  2. CAPRIN1/TYMS/MTHFD2 axis promotes EMT process in nasopharyngeal carcinoma development.2025The international journal of biochemistry & cell biology
  3. Chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Who really needs it.2023Cancer medicine免费全文
  4. Efficacy and toxicities of elective upper-neck irradiation versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: A meta-analysis.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  5. Effects of Baduanjin exercise in nasopharyngeal carcinoma patients after chemoradiotherapy: a randomized controlled trial.2022Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerRCT
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
PubMed 以外找到的论文(未计入)5
  1. Assessment Tools for Health‐Related Quality of Life in Patients With Nasopharyngeal Carcinoma: A Systematic Review of Psychometric Properties2025European Journal of Cancer Care综述
  2. ctDNA-guided treatment stratification for nasopharyngeal carcinoma patients: A retrospective cohort.2025Journal of Clinical Oncology论文
  3. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figshare数据集
  4. Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis2022Figshare综述
  5. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncology会议摘要

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.2%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 0020222023: 2220232024: 1120242025: 002025

沈阳有 2 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。

这些数字背后的记录
研究主题早期发现与内镜分子标志物与基因免疫治疗
论文中的科室消化/肝病科肿瘤内科放疗科
牵头的论文7
  1. Screening and verification of hub genes in esophageal squamous cell carcinoma by integrated analysis.2024Scientific reports免费全文
  2. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.2023BMC cancer免费全文
  3. Mucosal esophageal carcinoma following endoscopic submucosal dissection with giant gastric metastasis: A case report and review of literature.2023World journal of gastroenterology免费全文
  4. circRNA_141539 can serve as an oncogenic factor in esophageal squamous cell carcinoma by sponging miR-4469 and activating CDK3 gene.2021Aging免费全文
  5. LncRNA LINC00467 acted as an oncogene in esophageal squamous cell carcinoma by accelerating cell proliferation and preventing cell apoptosis via the miR-485-5p/DPAGT1 axis.2021Journal of gastroenterology and hepatology
  6. High expression of CIN85 promotes proliferation and invasion of human esophageal squamous cell carcinoma.2021Molecular medicine reports免费全文
  7. Clinical analysis of 117 cases with synchronous multiple primary esophageal squamous cell carcinomas.2021The Korean journal of internal medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma进行中,不再招募NCT04848753研究中心III期2021-05 启动
  2. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  3. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma状态不明NCT02409186研究中心III期2015-03 启动
PubMed 以外找到的论文(未计入)26
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncology论文
  2. An organ-preserving strategy in patients with esophageal squamous cell carcinoma treated with immunochemotherapy.2025Journal of Clinical Oncology会议摘要
  3. 418P A PET/CT image-based deep learning approach for precise survival prognosis and clinical management of treatments in patients with esophageal carcinoma2024Annals of Oncology论文
  4. The intricate mechanism through which UMODL1 accelerating tumor proliferation of Her-2 positive breast cancer as well as trastuzumab resistance2024Research Square预印本
  5. 1573P Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC2023Annals of Oncology论文
  6. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  7. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  8. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  9. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figshare数据集
  10. Proper prognostic classification of histopathologic response to neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma2023Research Square预印本
  11. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  12. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  13. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  14. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  15. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  16. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  17. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  18. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  19. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  20. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figshare数据集
  21. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figshare数据集
  22. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figshare数据集
  23. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figshare数据集
  24. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physics论文
  25. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncology会议摘要
  26. RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling2022Figshare数据集

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 61 篇,占 0.4%。

牵头论文
61
2021–2025 年
牵头试验
6
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 111120212022: 121220222023: 8820232024: 151520242025: 11112025

沈阳有 4 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
    分期
    II期
    开始
    2026-05
    登记号
    NCT07483359

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:中国医科大学附属第一医院沈阳

  2. 即将招募
    Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
    分期
    II期
    开始
    2026-10
    登记号
    NCT07557914

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:中国医科大学附属第一医院沈阳

  3. 正在招募
    First in Human Study of SIM0610 in Solid Tumors
    分期
    I期
    开始
    2026-01
    登记号
    NCT07348211

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、哈尔滨、沈阳、重庆

  4. 正在招募
    JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
    分期
    II期
    开始
    2025-05
    登记号
    NCT06954467

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、合肥、哈尔滨、沈阳、郑州、长沙

  5. 正在招募
    Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
    分期
    II期
    开始
    2025-11
    登记号
    NCT07239245

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医学科学院肿瘤医院;另有 2 家列出的医院为研究中心北京、沈阳、郑州

  6. 正在招募
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    分期
    II期
    开始
    2025-06
    登记号
    NCT07327034

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 39 家列出的医院为研究中心上海、北京、南京、南宁、南昌、南通、合肥、天津、广州、徐州、成都、杭州、桂林、武汉、沈阳、济南、福州、西安、赣州、郑州、重庆、银川、长春、长沙

  7. 正在招募
    CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
    分期
    I期
    开始
    2023-10
    登记号
    NCT06560827

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、武汉、沈阳、福州、郑州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题复发与预后免疫与靶向药物局部治疗(消融、TACE、HAIC)
论文中的科室影像/核医学科普外/肝胆胰外科肿瘤内科消化/肝病科
牵头的论文61
  1. Non-Gaussian diffusion MRI models for preoperative assessment of microvascular invasion in hepatocellular carcinoma.2026Abdominal radiology (New York)
  2. G6PD+CSV+ circulating tumor cells associated with portal vein tumor thrombus formation via EMT-ferroptosis crosstalk: a dual biomarker for therapeutic efficacy and prognosis prediction in hepatocellular carcinoma.2026Cancer letters
  3. Suppressing hyperthermia-induced up-regulated PD-L1 with a Sunitinib loaded Fe-Cu MOF: Strengthening immunogenic cell death to sensitize anti-PD-L1 effect following microwave ablation of hepatocellular carcinoma.2026Colloids and surfaces. B, Biointerfaces
  4. Research progress and therapeutic strategies in hepatocellular carcinoma metabolic reprogramming.2026Journal of advanced research免费全文
  5. Balloon-occluded versus conventional transarterial chemoembolization for the treatment of early to intermediate stage hepatocellular carcinoma: a meta-analysis and trial sequential analysis.2025BMC cancer免费全文
  6. Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): st2025BMJ open免费全文
  7. The multifaceted roles of macrophages in the transition from hepatitis to hepatocellular carcinoma: From mechanisms to therapeutic strategies.2025Biochimica et biophysica acta. Molecular basis of disease
  8. Transcriptional regulation of ATOX1 by PRRX2 impacts the progression and cuproptosis of hepatocellular carcinoma.2025Cellular signalling
  9. Complications of transarterial radioembolization in hepatic malignancies: Pathophysiological insights and management paradigms.2025European journal of radiology
  10. CD63-high macrophage-derived exosomal miR-6876-5p promotes hepatocellular carcinoma stemness via PTEN/Akt-mediated EMT pathway.2025Hepatology communications免费全文
  11. In vitro anticancer effects in hepatocellular carcinoma (HCC) and protein interaction study of xanthoangelol.2025International journal of biological macromolecules
  12. MRI-based radiomics predicts complete responses to initial transcatheter arterial chemoembolization in virus-associated early and intermediate stage HCC.2025Magnetic resonance imaging
  13. Predicting the outcome of transarterial chemoembolization combined with targeted immunotherapy for unresectable hepatocellular carcinoma based on MRI radiomics.2025Scientific reports免费全文
  14. NELL2 suppresses epithelial-mesenchymal transition and induces ferroptosis via notch signaling pathway in HCC.2025Scientific reports免费全文
  15. Artificial intelligence in hepatopathy diagnosis and treatment: Big data analytics, deep learning, and clinical prediction models.2025World journal of gastroenterology免费全文
  16. Deep Learning Model for Predicting Proliferative Hepatocellular Carcinoma Using Dynamic Contrast-Enhanced MRI: Implications for Early Recurrence Prediction Following Radical Resection.2024Academic radiology
  17. CD63 + tumor-associated macrophages drive the progression of hepatocellular carcinoma through the induction of epithelial-mesenchymal transition and lipid reprogramming.2024BMC cancer免费全文
  18. Long Noncoding RNAs MALAT1 and HOTTIP Act as Serum Biomarkers for Hepatocellular Carcinoma.2024Cancer control : journal of the Moffitt Cancer Center免费全文
  19. The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions.2024Frontiers in immunology免费全文
  20. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.2024Frontiers in immunology免费全文
  21. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis.2024Hepatology international
  22. The hepatic steatosis, steatohepatitis and metabolic dysfunction: distinct roles in hepatocellular carcinoma occurrence in chronic hepatitis B patients.2024Hepatology international免费全文
  23. Identification of PPAR-related differentially expressed genes liver hepatocellular carcinoma and construction of a prognostic model based on data analysis and molecular docking.2024Journal of cellular and molecular medicine免费全文
  24. Hemoglobin nanoclusters-mediated regulation of KPNA4 in hypoxic tumor microenvironment enhances photodynamic therapy in hepatocellular carcinoma.2024Journal of nanobiotechnology免费全文
  25. Identification of an m6A Natural Inhibitor, Lobeline, That Reverses Lenvatinib Resistance in Hepatocellular Tumors.2024Journal of natural products
  26. Combination strategies in advanced hepatocellular carcinoma: the CARES-310 trial.2024Lancet (London, England)
  27. Nicotinamide mononucleotide induces autophagy and ferroptosis via AMPK/mTOR pathway in hepatocellular carcinoma.2024Molecular carcinogenesis
  28. Multimodal Theranostic Nanoparticles for Necrosis Targeting, Fluorescence/SPECT Imaging, and Radiotherapy of Residual Tumors after Hepatocellular Carcinoma Ablation.2024Molecular pharmaceutics
  29. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis.2024Pharmacology & therapeutics
  30. Reserpine, a novel N6-methyladenosine regulator, reverses Lenvatinib resistance in hepatocellular carcinoma.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  31. Cell division cycle-associated 8 is a prognostic biomarker related to immune invasion in hepatocellular carcinoma.2023Cancer medicine免费全文
  32. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.2023Cancer metastasis reviews
  33. Survival benefit of perioperative locoregional adjuvant treatment for hepatocellular carcinoma with portal vein tumor thrombosis: A systematic review and Bayesian network meta-analysis.2023Critical reviews in oncology/hematology
  34. Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study.2023Expert review of anticancer therapy
  35. Characterizing ligand-receptor interactions and unveiling the pro-tumorigenic role of CCL16-CCR1 axis in the microenvironment of hepatocellular carcinoma.2023Frontiers in immunology免费全文
  36. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.2023Human cell
  37. CDK1-SRC Interaction-Dependent Transcriptional Activation of HSP90AB1 Promotes Antitumor Immunity in Hepatocellular Carcinoma.2023Journal of proteome research
  38. Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?2023Molecular cancer免费全文
  39. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.2022Aging免费全文
  40. Nomogram-based development and evaluation for predictions of 30-day and 1-year survival in patients with spontaneously ruptured hepatocellular carcinoma.2022BMC cancer免费全文
  41. Tumor and peritumor radiomics analysis based on contrast-enhanced CT for predicting early and late recurrence of hepatocellular carcinoma after liver resection.2022BMC cancer免费全文
  42. miR-3168 promotes hepatocellular carcinoma progression via downregulating p53.2022Carcinogenesis
  43. miR-3154 promotes hepatocellular carcinoma progression via suppressing HNF4α.2022Carcinogenesis
  44. Downregulation of MUC15 by miR-183-5p.1 promotes liver tumor-initiating cells properties and tumorigenesis via regulating c-MET/PI3K/AKT/SOX2 axis.2022Cell death & disease免费全文
  45. Predicting Prognosis of Hepatocellular Carcinoma Patients Based on the Expression Signatures of Mitophagy Genes.2022Disease markers免费全文
  46. Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma.2022Hepatology international免费全文
  47. A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients.2022IET systems biology免费全文
  48. Mig-6 Inhibits Autophagy in HCC Cell Lines by Modulating miR-193a-3p.2022International journal of medical sciences免费全文
  49. Hepatocellular carcinoma: Novel understandings and therapeutic strategies based on bile acids (Review).2022International journal of oncology免费全文
  50. Identification of the Mechanism of Matrine Combined with Glycyrrhizin for Hepatocellular Carcinoma Treatment through Network Pharmacology and Bioinformatics Analysis.2022Oxidative medicine and cellular longevity免费全文
  51. Evaluation of the efficacy and postoperative outcomes of hydrodissection-assisted microwave ablation for subcapsular hepatocellular carcinoma and colorectal liver metastases.2021Abdominal radiology (New York)
  52. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study.2021BMC cancer免费全文
  53. Brachytherapy with Iodine-125 seeds for treatment of portal vein-branch tumor thrombus in patients with hepatocellular carcinoma.2021BMC cancer免费全文
  54. Generation of combined hepatocellular-cholangiocarcinoma through transdifferentiation and dedifferentiation in p53-knockout mice.2021Cancer science免费全文
  55. Aloin decelerates the progression of hepatocellular carcinoma through circ_0011385/miR-149-5p/WT1 axis.2021Cell cycle (Georgetown, Tex.)免费全文
  56. MicroRNA-1178-3p suppresses the growth of hepatocellular carcinoma by regulating transducin (beta)-like 1 X-linked receptor 1.2021Human cell
  57. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.2021International journal of nanomedicine免费全文
  58. Impact of low serum hemoglobin on development of contrast-induced nephropathy (CIN) in patients with hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE).2021International urology and nephrology
  59. Nanomedicine Approach to Immunotherapy of Hepatocellular Carcinoma.2021Journal of biomedical nanotechnology
  60. Identification of CD8+ T Cell-Related Genes: Correlations with Immune Phenotypes and Outcomes of Liver Cancer.2021Journal of immunology research免费全文
  61. Favorable response to multimodal treatment in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus and left adrenal gland metastasis: A case report and literature review.2021Medicine免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)17
  1. Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus正在招募NCT07483359牵头方II期2026-05 启动
  2. HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC状态不明NCT06632106牵头方2024-08 启动
  3. HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC状态不明NCT06632093牵头方2024-09 启动
  4. HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)已完成NCT06631326牵头方2021-01 启动
  5. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC状态不明NCT02018757牵头方II期2014-01 启动
  6. Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes即将招募NCT07557914牵头方(推断)II期2026-10 启动
  7. First in Human Study of SIM0610 in Solid Tumors正在招募NCT07348211研究中心I期2026-01 启动
  8. Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo正在招募NCT07239245研究中心II期2025-11 启动
  9. JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma正在招募NCT06954467研究中心II期2025-05 启动
  10. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression正在招募NCT07327034研究中心II期2025-06 启动
  11. CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection正在招募NCT06560827研究中心I期2023-10 启动
  12. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere进行中,不再招募NCT06900543研究中心III期2025-04 启动
  13. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC已完成NCT04948697研究中心II期2021-08 启动
  14. Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC状态不明NCT05339321研究中心I期2021-04 启动
  15. A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors进行中,不再招募NCT06239155研究中心I/II期2019-09 启动
  16. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation已完成NCT04102098研究中心III期2019-12 启动
  17. Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC状态不明NCT03313596研究中心III期2013-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 109 篇,占 1.1%。

牵头论文
109
2021–2025 年
牵头试验
10
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
9
由其他机构牵头
每年牵头的论文数
2021: 303020212022: 212120222023: 161620232024: 202020242025: 19192025

沈阳有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 10

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
    分期
    II期
    开始
    2024-12
    登记号
    NCT06666166

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:中国医科大学附属第一医院沈阳

  2. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 64 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue
    分期
    不分期
    开始
    2025-01
    登记号
    NCT06830018

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心沈阳

  4. 正在招募
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    分期
    不分期
    开始
    2024-09
    登记号
    NCT06128252

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 11 家列出的医院为研究中心上海、乌鲁木齐、南京、武汉、沈阳、西安、重庆

  5. 正在招募
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
    分期
    II/III期
    开始
    2024-08
    登记号
    NCT06504732

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心哈尔滨、沈阳

  6. 正在招募
    A Phase 2 Clinical Study of ABSK061 and ABSK043
    分期
    II期
    开始
    2024-11
    登记号
    NCT06632262

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、厦门、哈尔滨、天津、太原、徐州、成都、杭州、武汉、沈阳、石家庄、襄阳、贵阳、郑州

  7. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

  8. 正在招募
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    分期
    I/II期
    开始
    2022-01
    登记号
    NCT05150691

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 34 家列出的医院为研究中心上海、北京、南宁、厦门、合肥、天津、安阳、广州、徐州、无锡、杭州、武汉、沈阳、济南、温州、烟台、石家庄、蚌埠、西安、郑州、重庆、长春、长沙

  9. 正在招募
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    分期
    不分期
    开始
    2022-09
    登记号
    NCT05450835

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学南方医院;另有 7 家列出的医院为研究中心广州、汕头、沈阳、长春、长沙

  10. 正在招募
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    分期
    I期
    开始
    2021-06
    登记号
    NCT04900818

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、合肥、哈尔滨、天津、广州、杭州、武汉、沈阳、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题腹膜转移与晚期影像与人工智能免疫与靶向药物
论文中的科室肿瘤内科普外/肝胆胰外科消化/肝病科病理/检验科
牵头的论文109
  1. Targeting the SOX9/TIMP1 Axis with iRGD-Conjugated Nanoplatform Enhances Dendritic Cell Function and Photodynamic Immunotherapy in Gastric Cancer.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Comparative short-term outcomes of peri-operative immunotherapy and targeted therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. Gastric cancer causing Schnitzler's metastasis: case report and systematic review of the features.2025Acta oncologica (Stockholm, Sweden)免费全文
  4. Frailty as a predictor of postoperative outcomes in older gastroesophageal cancer patients: a systematic review and meta-analysis.2025BMC geriatrics免费全文
  5. Helicobacter pylori SlyD stabilizes TPT1 via hnRNPK and enhances OCT1-mediated CDX2 transcriptional activation to drive gastric intestinal metaplasia.2025BMC medicine免费全文
  6. Advanced ensemble staking model employing cfDNA fragmentation for early detection of esophageal and gastric cancer.2025Cancer letters
  7. De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming.2025Cell death & disease免费全文
  8. Phytosphingosine suppresses gastric cancer through SFRP4/β-catenin axis-mediated Wnt signaling pathway inhibition.2025Chemico-biological interactions
  9. Development of a Risk Prediction Model for Preoperative Pre-Frailty in Elderly Patients with Gastric Cancer.2025Clinical interventions in aging免费全文
  10. Comprehensive Analysis of the ADCY Family and Identification of ADCY5 as a Prognostic Marker for Gastric Cancer.2025Frontiers in bioscience (Landmark edition)
  11. Prognostic performance of examined lymph nodes, lymph node ratio, and positive lymph nodes in gastric cancer: a competing risk model study.2025Frontiers in endocrinology免费全文
  12. Immune analysis according to Lauren type for gastric cancer and its significance in individual treatment and prognostic prediction.2025Frontiers in immunology免费全文
  13. Comprehensive pan-cancer analysis of USP35 and validation of its role in gastric cancer.2025Human genomics免费全文
  14. Microsatellite-Stable Gastric Cancer Can be Classified into 2 Molecular Subtypes with Different Immunotherapy Response and Prognosis Based on Gene Sequencing and Computational Pathology.2025Laboratory investigation; a journal of technical methods and pathology
  15. Primary solitary fibrous tumor of the stomach: A case report and a review of literature.2025Medicine免费全文
  16. Advances in 16S rRNA-Based Microbial Biomarkers for Gastric Cancer Diagnosis and Prognosis.2025Microbial biotechnology免费全文
  17. T-bet+CD8+ T cells govern anti-PD-1 responses in microsatellite-stable gastric cancers.2025Nature communications免费全文
  18. The interplay between oxytocin receptor and YAP in regulating gastric cancer progression.2025Oncogene
  19. Machine learning reveals glycolytic key gene in gastric cancer prognosis.2025Scientific reports免费全文
  20. Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance.2025Seminars in oncology
  21. Gastric Cancer Models Developed via GelMA 3D Bioprinting Accurately Mimic Cancer Hallmarks, Tumor Microenvironment Features, and Drug Responses.2025Small (Weinheim an der Bergstrasse, Germany)
  22. Nanomechanical Analysis of Living Small Extracellular Vesicles to Identify Gastric Cancer Cell Malignancy Based on a Biomimetic Peritoneum.2024ACS nano免费全文
  23. Frailty as a predictor of adverse outcomes in patients with gastric cancer: A systematic review and meta-analysis of 75,357 patients.2024Ageing research reviews
  24. Integrating transcriptomic data and digital pathology for NRG-based prediction of prognosis and therapy response in gastric cancer.2024Annals of medicine免费全文
  25. Radiomics analysis in predicting vascular invasion in gastric cancer based on enhanced CT: a preliminary study.2024BMC cancer免费全文
  26. Effect of prehabilitation for patients undergoing gastric cancer surgery: a protocol of a systematic review and meta-analysis.2024BMJ open免费全文
  27. Mechanisms of HIF1A-mediated immune evasion in gastric cancer and the impact on therapy resistance.2024Cell biology and toxicology免费全文
  28. Interpretable multi-modal artificial intelligence model for predicting gastric cancer response to neoadjuvant chemotherapy.2024Cell reports. Medicine免费全文
  29. Deep learning and machine learning approaches to classify stomach distant metastatic tumors using DNA methylation profiles.2024Computers in biology and medicine
  30. Causal relationships between coffee intake, apolipoprotein B and gastric, colorectal, and esophageal cancers: univariable and multivariable Mendelian randomization.2024European journal of nutrition
  31. LOXL1 promotes gastric cancer progression by β-catenin-cyclinD mediated proliferation.2024Experimental cell research
  32. Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.2024Frontiers in immunology免费全文
  33. TM-Score predicts immunotherapy efficacy and improves the performance of the machine learning prognostic model in gastric cancer.2024International immunopharmacology
  34. A bibliometric analysis of gastric cancer liver metastases: advances in mechanisms of occurrence and treatment options.2024International journal of surgery (London, England)免费全文
  35. Exploring new frontiers: cell surface vimentin as an emerging marker for circulating tumor cells and a promising therapeutic target in advanced gastric Cancer.2024Journal of experimental & clinical cancer research : CR免费全文
  36. Gastric intestinal metaplasia: progress and remaining challenges.2024Journal of gastroenterology
  37. Hypoxia-induced LAMB2-enriched extracellular vesicles promote peritoneal metastasis in gastric cancer via the ROCK1-CAV1-Rab11 axis.2024Oncogene
  38. Prognostic and predictive value of pathohistological features in gastric cancer and identification of SLITRK4 as a potential biomarker for gastric cancer.2024Scientific reports免费全文
  39. Circulating long noncoding RNA, Zfpm2-As1, and XIST based on medical data analysis are potential plasma biomarkers for gastric cancer diagnosis.2024Technology and health care : official journal of the European Society for Engineering and Medicine免费全文
  40. Alternative Splicing Factor Heterogeneous Nuclear Ribonucleoprotein U as a Promising Biomarker for Gastric Cancer Risk and Prognosis with Tumor-Promoting Properties.2024The American journal of pathology
  41. Comment on: Randomized clinical trial on D2 lymphadenectomy versus D2 lymphadenectomy plus complete mesogastric excision in patients undergoing gastrectomy for cancer (DCGC01 study).2024The British journal of surgery
  42. CRIP1 Reshapes the Gastric Cancer Microenvironment to Facilitate Development of Lymphatic Metastasis.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  43. Individualized Choice of Simultaneous Cholecystectomy in Patients with Gastric Cancer: A Systematic Review and Meta-analysis.2023Annals of surgical oncology
  44. ASO Author Reflections: The Safety Analysis and Potential Indications of Simultaneous Cholecystectomy for Gastric Cancer.2023Annals of surgical oncology
  45. Association of perioperative allogeneic blood transfusions and long-term outcomes following radical surgery for gastric and colorectal cancers: systematic review and meta-analysis of propensity-adjusted observational studies.2023BJS open免费全文
  46. Expression characteristics and their functional role of IGFBP gene family in pan-cancer.2023BMC cancer免费全文
  47. Long noncoding RNA PSMA3-AS1 functions as a competing endogenous RNA to promote gastric cancer progression by regulating the miR-329-3p/ALDOA axis.2023Biology direct免费全文
  48. Characterization of RNA modifications in gastric cancer to identify prognosis-relevant gene signatures.2023Cancer medicine免费全文
  49. Towards an optimal model for gastric cancer peritoneal metastasis: current challenges and future directions.2023EBioMedicine免费全文
  50. Separation and single-cell analysis for free gastric cancer cells in ascites and peritoneal lavages based on microfluidic chips.2023EBioMedicine免费全文
  51. Efficacy and safety of CalliSpheres® microspheres drug-eluting beads transarterial chemoembolization in GCLM combined trans-arterial infusion therapy for treating primary focus of gastric cancer: a multi-center retrospective study.2023Expert review of anticancer therapy
  52. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis.2023Nature communications免费全文
  53. Prognostic values of myosteatosis for overall survival in patients with gastric cancers: A meta-analysis with trial sequential analysis.2023Nutrition (Burbank, Los Angeles County, Calif.)
  54. circDYRK1A tethers biological behaviors of gastric carcinoma using novel bioinformatics analysis and experimental validations.2023Scientific reports免费全文
  55. Deep Learning-Based Stratification of Gastric Cancer Patients from Hematoxylin and Eosin-Stained Whole Slide Images by Predicting Molecular Features for Immunotherapy Response.2023The American journal of pathology
  56. FN1 mRNA 3'-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3'-UTR-let-7i-5p-THBS1 axis.2023Theranostics免费全文
  57. Leveraging existing 16S rRNA microbial data to identify diagnostic biomarker in Chinese patients with gastric cancer: a systematic meta-analysis.2023mSystems免费全文
  58. Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis.2022Annals of surgical oncology
  59. ASO Author Reflections: Chemoradiotherapy Versus Chemotherapy, Which One Is Better for Resectable Gastric Cancer Patients?2022Annals of surgical oncology
  60. ASO Author Reflections: Clinical Research and Application Prospect of HIPEC Combined with Surgery in Advanced Gastric Cancer.2022Annals of surgical oncology
  61. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages.2022Annals of surgical oncology
  62. Abnormally Expressed lncRNAs as Potential Biomarkers for Gastric Cancer Risk: A Diagnostic Meta-Bioinformatics Analysis.2022BioMed research international免费全文
  63. Hsa_circ_0005230 is up-regulated and promotes gastric cancer cell invasion and migration via regulating the miR-1299/RHOT1 axis.2022Bioengineered免费全文
  64. RBMS1 promotes gastric cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling.2022Cell death & disease免费全文
  65. Gastric Organoids: Progress and Remaining Challenges.2022Cellular and molecular gastroenterology and hepatology免费全文
  66. Kang-Ai Injection Inhibits Gastric Cancer Cells Proliferation through IL-6/STAT3 Pathway.2022Chinese journal of integrative medicine
  67. HER2-Negative Schnitzler Metastasis to the Rectum Detected Using 18 F-FDG PET/CT.2022Clinical nuclear medicine
  68. Discordant Metabolic Response on 18F-FDG PET/CT in Synchronous Primary Gastric Lymphoma and Gastric Adenocarcinoma.2022Clinical nuclear medicine免费全文
  69. Site-Specific Hypermethylation of SST 1stExon as a Biomarker for Predicting the Risk of Gastrointestinal Tract Cancers.2022Disease markers免费全文
  70. Identification of RFX5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma.2022European journal of medical research免费全文
  71. Predicting functional circular RNA-based competitive endogenous RNA network in gastric carcinoma using novel bioinformatics analysis.2022Experimental biology and medicine (Maywood, N.J.)免费全文
  72. PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis.2022Frontiers in immunology免费全文
  73. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.2022Frontiers in immunology免费全文
  74. Sarcopenia and a 5-mRNA risk module as a combined factor to predict prognosis for patients with stomach adenocarcinoma.2022Genomics
  75. RBPMS2, as a novel biomarker for predicting lymph node metastasis, guides therapeutic regimens in gastric cancer.2022Human cell
  76. Involvement of CXCL17 and GPR35 in Gastric Cancer Initiation and Progression.2022International journal of molecular sciences免费全文
  77. GRK3 is a poor prognosticator and serves as a therapeutic target in advanced gastric adenocarcinoma.2022Journal of experimental & clinical cancer research : CR免费全文
  78. Identification of specific role of SNX family in gastric cancer prognosis evaluation.2022Scientific reports免费全文
  79. Primary gastric melanoma with pancreatic metastasis: a case report.2021Annals of palliative medicine
  80. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature.2021BMC cancer免费全文
  81. Central lymph node metastasis is predictive of survival in advanced gastric cancer patients treated with D2 lymphadenectomy.2021BMC gastroenterology免费全文
  82. Ubiquitin-associated protein 2 like (UBAP2L) enhances growth and metastasis of gastric cancer cells.2021Bioengineered免费全文
  83. High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer.2021Bioscience reports免费全文
  84. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.2021Cellular & molecular biology letters免费全文
  85. Circ_0049447 acts as a tumor suppressor in gastric cancer through reducing proliferation, migration, invasion, and epithelial-mesenchymal transition.2021Chinese medical journal免费全文
  86. Different clinicopathologic features and prognostic significance of signet ring cell histology in early and locally advanced gastric cancer patients.2021Clinics and research in hepatology and gastroenterology
  87. Inhibitors Targeting YAP in Gastric Cancer: Current Status and Future Perspectives.2021Drug design, development and therapy免费全文
  88. Prognostic significance of palliative gastrectomy in incurable advanced gastric cancer: a retrospective cohort study and meta-analysis.2021European review for medical and pharmacological sciences
  89. Differentiated/undifferentiated mixed type is a prognostic factor for T2/T3 gastric cancer patients.2021Expert review of gastroenterology & hepatology
  90. Mutations of key driver genes in gastric cancer metastasis risk: a systematic review and meta-analysis.2021Expert review of molecular diagnostics
  91. Bufalin inhibits peritoneal dissemination of gastric cancer through endothelial nitric oxide synthase-mitogen-activated protein kinases signaling pathway.2021FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  92. A Dynamic Transcriptome Map of Different Tissue Microenvironment Cells Identified During Gastric Cancer Development Using Single-Cell RNA Sequencing.2021Frontiers in immunology免费全文
  93. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.2021Frontiers in immunology免费全文
  94. Pepsinogen C expression-related lncRNA/circRNA/mRNA profile and its co-mediated ceRNA network in gastric cancer.2021Functional & integrative genomics
  95. Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer.2021Future oncology (London, England)
  96. PDCD4 regulates apoptosis in human peritoneal mesothelial cells and promotes gastric cancer peritoneal metastasis.2021Histology and histopathology
  97. Integrative analysis-based identification and validation of a prognostic immune cell infiltration-based model for patients with advanced gastric cancer.2021International immunopharmacology
  98. Hsa_circ_001988 attenuates GC progression in vitro and in vivo via sponging miR-197-3p.2021Journal of cellular physiology
  99. The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.2021Journal of clinical laboratory analysis免费全文
  100. Increased Expression of LIPC Is Associated with Aggressive Phenotype of Borrmann Type 4 Gastric Cancer.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  101. LINC00242/miR-1-3p/G6PD axis regulates Warburg effect and affects gastric cancer proliferation and apoptosis.2021Molecular medicine (Cambridge, Mass.)免费全文
  102. Identifying Diagnostic and Prognostic Biomarkers and Candidate Therapeutic Drugs of Gastric Cancer Based on Transcriptomics and Single-Cell Sequencing.2021Pathology oncology research : POR免费全文
  103. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.2021PloS one免费全文
  104. Construction of an immune-related gene signature to predict survival and treatment outcome in gastric cancer.2021Science progress免费全文
  105. Positive lymph node ratio is an index in predicting prognosis for remnant gastric cancer with insufficient retrieved lymph node in R0 resection.2021Scientific reports免费全文
  106. Tumor-derived extracellular vesicles containing microRNA-1290 promote immune escape of cancer cells through the Grhl2/ZEB1/PD-L1 axis in gastric cancer.2021Translational research : the journal of laboratory and clinical medicine
  107. Circular RNA circVAPA promotes chemotherapy drug resistance in gastric cancer progression by regulating miR-125b-5p/STAT3 axis.2021World journal of gastroenterology免费全文
  108. A novel prognostic model based on epithelial-mesenchymal transition-related genes predicts patient survival in gastric cancer.2021World journal of surgical oncology免费全文
  109. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer.2020Frontiers in immunology免费全文
中文论文(未计入)5
  1. [Progress of individualized precision therapy for peritoneal metastasis in gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Integrated diagnosis and treatment of peritoneal metastasis in gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Call for attention to the value and challenge of liquid biopsy in diagnosis and treatment for peritoneal metastasis of gastric cancer].2024Zhonghua yi xue za zhi
  4. [Recent progress and future prospects of treatment for peritoneal metastasis in gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Standardized implementation of minimally invasive surgery for Siewert Ⅱ esophagogastric junction adenocarcinoma].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)35
  1. Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer状态不明NCT05208372牵头方2022-01 启动
  2. Gut Microbiota and Metabonomics状态不明NCT05205187牵头方2022-02 启动
  3. EDLS-clips in Endoscopic Full-thickness Resection已完成NCT07305038牵头方2022-03 启动
  4. Multi-center and Multi-modal Deep Learning Study of Gastric Cancer状态不明NCT05001321牵头方2021-07 启动
  5. SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer即将招募NCT06666166牵头方(推断)II期2024-12 启动
  6. A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method状态不明NCT06100003牵头方(推断)2023-10 启动
  7. Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma状态不明NCT04443036牵头方(推断)不分期2020-06 启动
  8. Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer状态不明NCT04286711牵头方(推断)I/II期2020-03 启动
  9. Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer状态不明NCT03915171牵头方(推断)不分期2019-03 启动
  10. S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites状态不明NCT03990103牵头方(推断)II期2017-11 启动
  11. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  12. Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue正在招募NCT06830018研究中心不分期2025-01 启动
  13. A Phase 2 Clinical Study of ABSK061 and ABSK043正在招募NCT06632262研究中心II期2024-11 启动
  14. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer正在招募NCT06128252研究中心不分期2024-09 启动
  15. To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer正在招募NCT06504732研究中心II/III期2024-08 启动
  16. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  17. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors正在招募NCT05150691研究中心I/II期2022-01 启动
  18. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method正在招募NCT05450835研究中心不分期2022-09 启动
  19. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors正在招募NCT04900818研究中心I期2021-06 启动
  20. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China已完成NCT06585501研究中心2024-08 启动
  21. Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma已终止NCT06206278研究中心II期2023-10 启动
  22. Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing状态不明NCT06036563研究中心2023-09 启动
  23. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  24. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  25. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction已完成NCT04661150研究中心II期2021-03 启动
  26. IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma已完成NCT05327231研究中心I期2020-07 启动
  27. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  28. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)进行中,不再招募NCT04152499研究中心I/II期2020-02 启动
  29. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  30. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  31. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  32. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  33. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery状态不明NCT02130752研究中心不分期2014-10 启动
  34. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  35. A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer已终止NCT01967875研究中心II期2013-07 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

沈阳有 1 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 1120242025: 112025

沈阳有 7 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
牵头的论文5
  1. FDG PET/CT in a Case of Primary Ewing Sarcoma of the Uterus.2025Clinical nuclear medicine
  2. Mitochondria in skeletal system-related diseases.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  3. Construction and validation of an oxidative-stress-related risk model for predicting the prognosis of osteosarcoma.2023Aging
  4. A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019.2021BMC cancer
  5. The inhibitory effect of CTAB on human osteosarcoma through the PI3K/AKT signaling pathway.2021International journal of oncology
早期论文(2016–2020 年)11
  1. Carboxypeptidase E-ΔN promotes migration, invasiveness, and epithelial-mesenchymal transition of human osteosarcoma cells via the Wnt-β-catenin pathway.2019Biochemistry and cell biology = Biochimie et biologie cellulaire
  2. Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.2019FEBS open bio
  3. LPS promote Osteosarcoma invasion and migration through TLR4/HOTAIR.2019Gene
  4. Marital Status and Survival in Osteosarcoma Patients: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database.2019Medical science monitor : international medical journal of experimental and clinical research
  5. Effect of lncRNA ANRIL knockdown on proliferation and cisplatin chemoresistance of osteosarcoma cells in vitro.2019Pathology, research and practice
  6. Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.2018Cell cycle (Georgetown, Tex.)
  7. Knockdown of pyruvate kinase type M2 suppresses tumor survival and invasion in osteosarcoma cells both in vitro and in vivo.2018Experimental cell research
  8. Long non-coding RNA NEAT1 promotes proliferation, migration and invasion of human osteosarcoma cells.2018International journal of medical sciences
  9. X-linked inhibitor of apoptosis protein inhibitor Embelin induces apoptosis via PI3K/Akt pathway and inhibits invasion in osteosarcoma cells.2018Journal of cancer research and therapeutics
  10. MicroRNA‑106a regulates the proliferation and invasion of human osteosarcoma cells by targeting VNN2.2018Oncology reports
  11. MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.1%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 0020232024: 0020242025: 222025

沈阳有 3 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科
牵头的论文6
  1. The efficacy of immunotherapy in the treatment of tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors: a systematic review and meta-analysis.2026Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  2. Age-dependent diminution of female prognostic advantage in gastrointestinal stromal tumors: a retrospective cohort analysis.2025Frontiers in immunology
  3. Impact of Gastrointestinal Bleeding on Prognosis and Associated Risk Factors in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-Analysis.2025The American surgeon
  4. The first case of a collision tumor of gastrointestinal stromal tumor and intravascular large B cell lymphoma.2022Annals of hematology
  5. Sarcopenia as a novel prognostic factor in the patients of primary localized gastrointestinal stromal tumor.2022BMC cancer
  6. Genomic Study of Chinese Quadruple-negative GISTs Using Next-generation Sequencing Technology.2021Applied immunohistochemistry & molecular morphology : AIMM
早期论文(2016–2020 年)5
  1. Is endoscopic resection more effective than laparoscopic resection in gastric gastrointestinal stromal tumours?2020European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. What is the clinical significance of the multivariate prediction model for GI stromal tumors with high malignant potential before endoscopic resection?2020Gastrointestinal endoscopy
  3. The epithelioid gastrointestinal stromal tumor with pulmonary metastasis: A rare case report and literature review.2020Medicine
  4. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).2020Pathology oncology research : POR
  5. The assessment of different risk classification systems for gastrointestinal stromal tumors (GISTs): the analytic results from the SEER database.2018Scandinavian journal of gastroenterology

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

沈阳有 5 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科病理/检验科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

沈阳有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
牵头的论文1
  1. FDG PET/CT in a Case of Primary Ewing Sarcoma of the Uterus.2025Clinical nuclear medicine

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.2%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

沈阳有 2 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    分期
    I期
    开始
    2026-05
    登记号
    NCT07477587

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛

  2. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题联合用药双抗与抗体药物复发与耐药
论文中的科室病理/检验科
牵头的论文4
  1. Global, regional, and national multiple myeloma burden from 1990 to 2021: a systematic analysis for of the Global Burden of Disease Study 2021.2025BMC public health免费全文
  2. Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis.2025Frontiers in immunology免费全文
  3. Megalosplenia as an initial manifestation of multiple myeloma with a novel CYLD gene mutation: A case report and literature review.2024Medicine免费全文
  4. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.2024Oncology research免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
  1. A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma状态不明NCT05448404牵头方不分期2022-03 启动
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma正在招募NCT07477587研究中心I期2026-05 启动
  3. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  4. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  5. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies进行中,不再招募NCT04684108研究中心I期2021-11 启动
  6. A Study of Ninlaro in Real World Clinical Practice in China已完成NCT04328662研究中心2020-05 启动
  7. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  8. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.进行中,不再招募NCT03539744研究中心III期2018-10 启动
  9. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年没有牵头B 细胞急性淋巴细胞白血病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

沈阳有 1 家医院列在B 细胞急性淋巴细胞白血病下全国有 88 家医院列在B 细胞急性淋巴细胞白血病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的B 细胞急性淋巴细胞白血病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

沈阳有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题EB病毒与感染诱因遗传与家族性诊断与预后
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

沈阳有 3 家医院列在血友病 A下全国有 132 家医院列在血友病 A下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

沈阳有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室病理/检验科
中文论文(未计入)1
  1. [Evaluation of Sysmex XN-3000 for Detection of Schistocyte].2022Zhongguo shi yan xue ye xue za zhi

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 1.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 1120242025: 222025

沈阳有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    分期
    II/III期
    开始
    2024-07
    登记号
    NCT06413654

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙

  2. 即将招募
    Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
    分期
    IV期
    开始
    2026-06
    登记号
    NCT07699770

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学唐都医院;另有 5 家列出的医院为研究中心北京、昆明、沈阳、西安、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题抗体与诊断预防复发急性发作治疗
论文中的科室神经内科眼科/神经眼科
牵头的论文6
  1. Distinct Inflammatory Profiles and Clinical Characteristics of NMOSD: A Comparative Analysis with NMOSD-like and Encephalitis-like MOG-AD.2025Journal of proteome research
  2. Effect of L-Carnitine Level on the Risk of Neuromyelitis Optica Spectrum Disorders: A Two-Sample Mendelian Randomization Study.2025Molecular neurobiology
  3. Blood-based inflammatory protein biomarker panel for the prediction of relapse and severity in patients with neuromyelitis optica spectrum disorder: A prospective cohort study.2024CNS neuroscience & therapeutics免费全文
  4. Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases.2023Frontiers in immunology免费全文
  5. Retina thickness in clinically affected and unaffected eyes in patients with aquaporin-4 immunoglobulin G antibody seropositive neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.2023Journal of neurology
  6. Field synopsis and systematic meta-analyses of genetic association studies in neuromyelitis optica.2021Autoimmunity reviews
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial即将招募NCT07699770研究中心IV期2026-06 启动
  2. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)正在招募NCT06413654研究中心II/III期2024-07 启动
PubMed 以外找到的论文(未计入)1
  1. New insights into mapping lesion and neurotransmitter distribution comparisons in MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders2024Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.4%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 1120232024: 1120242025: 112025

沈阳有 2 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的IgG4相关性疾病开放试验。

这些数字背后的记录
研究主题治疗与复发诊断与鉴别肾脏、腹膜后与血管
论文中的科室消化/肝病科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 9 篇,占 1.8%。

牵头论文
9
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 2220242025: 442025

沈阳有 2 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题抗体与诊断胸腺与胸腺切除生物制剂与补体抑制剂
论文中的科室神经内科眼科/神经眼科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

沈阳有 1 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

沈阳有 3 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Pathogenesis of liver injury in Takayasu arteritis: advanced understanding leads to new horizons.2020The Journal of international medical research
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis即将招募NCT07451665研究中心IV期2026-04 启动
  2. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)进行中,不再招募NCT04161898研究中心III期2020-02 启动
  3. Takayasu Arteritis Clinical Trial in China已完成NCT02981979研究中心不分期2016-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

沈阳有 6 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科
牵头的论文3
  1. Ubiquitin-specific peptidase 10 attenuates bleomycin-induced pulmonary fibrosis via modulating autophagy depending on sirtuin 6-mediated AKT/mTOR.2025Cell biology and toxicology
  2. SCARF2 is a target for chronic obstructive pulmonary disease: Evidence from multi-omics research and cohort validation.2024Aging cell
  3. Expression of S100A9 and KL-6 in common interstitial lung diseases.2022Medicine
早期论文(2016–2020 年)4
  1. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.2020Therapeutic advances in respiratory disease
  2. Subgroup Analysis for Chinese Patients Included in the INPULSIS® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis.2019Advances in therapyRCT
  3. Targeted regulation of fibroblast state by CRISPR-mediated CEBPA expression.2019Respiratory research
  4. [The expression and clinical role of KL-6 in serum and BALF of patients with different diffuse interstitial lung diseases].2016Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT04419558研究中心III期2020-09 启动
  2. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)已终止NCT03955146研究中心III期2019-06 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.4%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

沈阳有 2 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

法布雷病

Fabry disease

2021–2025 年没有牵头法布雷病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

沈阳有 1 家医院列在法布雷病下全国有 80 家医院列在法布雷病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的法布雷病开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Otological aspects of Fabry disease in patients with normal hearing.2019Nagoya journal of medical science

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

沈阳有 2 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 2220232024: 1120242025: 002025

沈阳有 3 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

成骨不全症

Osteogenesis imperfecta

2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

沈阳有 2 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

沈阳有 3 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、宝鸡、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  2. 正在招募
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    分期
    II/III期
    开始
    2023-02
    登记号
    NCT05749822

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心北京、南京、天津、广州、延安、成都、昆明、沈阳、西安、郑州、长沙

  3. 正在招募
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    分期
    III期
    开始
    2023-02
    登记号
    NCT05751967

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:空军军医大学西京医院;另有 6 家列出的医院为研究中心兰州、南京、天津、广州、成都、沈阳、西安

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科
牵头的论文1
  1. S100 calcium binding protein A6 and associated long noncoding ribonucleic acids as biomarkers in the diagnosis and staging of primary biliary cholangitis.2021World journal of gastroenterology
早期论文(2016–2020 年)1
  1. Identification of Marker Genes and Pathways in Patients with Primary Biliary Cholangitis.2020Journal of computational biology : a journal of computational molecular cell biology
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis正在招募NCT05749822研究中心II/III期2023-02 启动
  3. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis正在招募NCT05751967研究中心III期2023-02 启动
  4. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis进行中,不再招募NCT06174402研究中心II/III期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

沈阳有 2 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。

这些数字背后的记录
论文中的科室消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性大疱性表皮松解症

Inherited epidermolysis bullosa

2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.8%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

沈阳有 1 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

遗传性血管性水肿

Hereditary angioedema

2021–2025 年没有牵头遗传性血管性水肿的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

沈阳有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China已完成NCT06346899研究中心2024-07 启动

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

中国医科大学附属第一医院

First Hospital of China Medical University

沈阳

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
First Affiliated Hospital of China Medical University; College of Basic Medical Science and The First Affiliated Hospital; College of Basic Medical Sciences and First Affiliated Hospital; and First Affiliated Hospital of China Medical University

提出更正下载数据